Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis

Table 2

Survivals of patients with exon 19 deletion and exon 21 Leu858 Arg mutation receiving EGFR-TKIs plus antiangiogenic agents and EGFR-TKIs.

Trials	EGFR mutation type	PFS		OS
		HR	95% CI	HR	95% CI
JO25567	Exon 19 deletion	0.41	0.24–0.72	0.79	0.44–1.44
	Exon 21 Leu858 arg mutation	0.67	0.38–1.18	0.83	0.46–1.49
NEJ026	Exon 19 deletion	0.69	0.41–1.16
	Exon 21 Leu858 arg mutation	0.57	0.33–0.97
RELAY	Exon 19 deletion	0.65	0.47–0.90
	Exon 21 Leu858 arg mutation	0.62	0.44–0.87
NCT01532089	Exon 19 deletion	0.83	0.47–1.47	0.34	0.16–0.72
	Exon 21 Leu858 arg mutation	Reference		Reference
ARTEMIS	Exon 19 deletion	0.62	0.42–0.93
	Exon 21 Leu858 arg mutation	0.50	0.32–0.77
ACTIVE	Exon 19 deletion	0.67	0.45–0.99
	Exon 21 Leu858 arg mutation	0.72	0.48–1.09

EGFR: epidermal growth factor receptor. HR: hazard ratio. CI: confidence interval. PFS: progression-free survival. OS: overall survival.